National Securities Corp analyst Ben Klieve maintained a Buy rating on Arcadia Biosciences (RKDA) today. The company’s shares closed yesterday at $4.03.
According to TipRanks.com, Klieve is a 4-star analyst with an average return of 8.9% and a 50.0% success rate. Klieve covers the Consumer Goods sector, focusing on stocks such as Yield10 Bioscience Inc, S&W Seed Company, and Marrone Bio.
Arcadia Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $14, a 247.4% upside from current levels. In a report issued on June 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $14 price target.
See today’s analyst top recommended stocks >>
Based on Arcadia Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.61 million. In comparison, last year the company had a GAAP net loss of $10.62 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcadia Biosciences, Inc. is an agricultural biotechnology company which engages in the development of agricultural products for the improvement of the environment and human health. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers.
